This is a distressed financing that provides a short-term cash infusion but at an extremely high cost and with severe dilution risk. The conversion price of $0.075 per share, combined with full-ratchet anti-dilution protection, means any future equity issuance at a lower price will further dilute common holders. The Chapter 11 proceedings of the diagnostics subsidiaries create significant uncertainty around the recovery value of the company's largest asset (a $9.99 million secured note from the debtors). Traders should monitor the bankruptcy court's approval of the plan of reorganization and the company's ability to meet its weekly installment payments, as a default would trigger a 110% penalty and accelerated conversion at an even deeper discount.
Price Chart
Executive Summary
ProPhase Labs entered into a senior secured convertible loan agreement with J.J. Astor & Co. for $1.5 million, which carries a $2.085 million face value (a 1.39x factor rate). The company received net proceeds of only $1.02 million after fees and a $300k payment reserve. The loan is structured as a distressed financing tied to the Chapter 11 bankruptcy of three of ProPhase's subsidiaries, with CEO Ted Karkus personally guaranteeing the debt. The highly dilutive conversion terms ($0.075/share, subject to ratchet) and the company's delisted status on the OTC market signal severe financial distress, making this filing bearish for common equity holders.
Key Financial Metrics
Key Facts
- ProPhase Labs borrowed $1.5 million from J.J. Astor & Co. via a senior secured convertible note with a $2.085 million original principal amount (1.39x factor rate).
- Net proceeds to the company were only $1.02 million after a $60,000 origination fee and a $300,000 payment reserve for the first 15 weekly installments.
- The note matures on July 31, 2027, and is payable in 52 weekly installments.
- The conversion price is $0.075 per share, subject to full-ratchet anti-dilution protection, with a make-whole provision if the market price is lower.
- Three of ProPhase's subsidiaries (ProPhase Diagnostics NJ, Inc., ProPhase Diagnostics NY, Inc., and ProPhase Diagnostics, Inc.) are debtors in a jointly administered Chapter 11 bankruptcy case (Case No. 25-19833 CMG).
- CEO Ted Karkus personally guaranteed the loan via an Affiliate Guaranty Agreement.
- The company's common stock has been delisted from Nasdaq for failing to meet the $1.00 bid price rule and now trades on the OTC market.
- The loan is secured by a senior priority lien on all assets of the company and its subsidiaries, with a deposit account control agreement (DACA) giving the lender control over company deposits.
- 75% of net collections from the bankruptcy estate's receivables (CMC Waterfall Distributions) will be paid directly to the lender until the note is repaid.
- The company must hold a stockholder meeting to increase authorized shares and seek Nasdaq re-listing, including a reverse stock split.
Financial Impact
The company received $1.02 million in net cash but incurred a $2.085 million face-value debt obligation. The effective interest rate is extremely high given the 1.39x factor rate, and the conversion price of $0.075 per share implies massive dilution for existing common shareholders if the note is converted.
Risk Factors
- Default risk on weekly installment payments, triggering a 110% penalty and accelerated conversion at a deep discount.
- Massive dilution to common equity if the lender converts the note at $0.075 per share, especially given the full-ratchet anti-dilution clause.
- The company's subsidiaries are in Chapter 11 bankruptcy, creating uncertainty around the collectability of the $9.99 million intercompany note.
- Failure to regain Nasdaq listing could trigger an event of default under the loan agreement.
- The lender has a right of first refusal on any DIP financing, giving it significant control over the bankruptcy process.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (PRPH) — Batch item 1 | 0001493152-26-036383 |
| Exhibit: ex10-2.htm | 0001493152-26-036383 |
| Document: form8-k.htm | 0001493152-26-036383 |
| Document: 0001493152-26-036383-index-headers.html | 0001493152-26-036383 |
| Document: 0001493152-26-036383-index.html | 0001493152-26-036383 |
| Document: 0001493152-26-036383.txt | 0001493152-26-036383 |
| 8-K Filing (PRPH) — Batch item 7 | 0001493152-26-036383 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $0.3626 | awaiting T+20 | — | $0.008600 (−97.63%) |
Aug 6, 2026 11w ago | 8-K | $0.3626 $0.3626 | · 0.00% | ▼ −0.40% | $0.008600 (+97.63%) |
Jul 9, 2026 15w ago | 10-Q/A | $0.0800 $0.0400 | ▲ +50.00% | ▲ +52.24% | $0.008600 (+89.25%) |
Jul 7, 2026 16w ago | 10-Q/A | $0.0900 $0.0480 | ▲ +46.67% | ▲ +49.83% | $0.008600 (+90.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers